Literature DB >> 21559821

Downregulation of caspase-10 predicting poor survival after resection of stage II colorectal cancer.

Xiao-Gang Shen1, Cun Wang, Yuan Li, Bin Zhou, Bin Xu, Lie Yang, Zong-Guang Zhou, Xiao-Feng Sun.   

Abstract

PURPOSE: The aim of this study was to evaluate the prevalence and clinical significance of caspase-10 mRNA expression in stage II colorectal cancer.
METHODS: Quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) was used to analyze caspase-10 expression in cancer tissue and corresponding normal mucosa from 120 patients with stage II colorectal cancer. Variables were analyzed by Chi-square test or Fisher's exact test. Survival was evaluated with method of Kaplan-Meier. Multivariate analysis was performed with Cox's proportional hazards model.
RESULTS: The expression of caspase-10 mRNA was found to be downregulated in cancer tissue compared to normal mucosa (P = 0.001). Poorly differentiated cancer showed lower mRNA expression than cancer with greater differentiation (P = 0.031). Univariate survival curves, estimated using the method of Kaplan-Meier, defined a significant association between caspase-10 expression and both overall survival (P = 0.012) and disease-free survival (P = 0.021). A multivariate analysis, performed by Cox's proportional hazards regression model, confirmed that a low caspase-10 expression was the only significant factor to predict poor prognosis in patients with stage II colorectal cancer.
CONCLUSION: Our data indicate that caspase-10 expression, measured by quantitative real-time RT-PCR, is a possible prognostic factor in patients with stage II colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21559821     DOI: 10.1007/s00384-011-1239-z

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  40 in total

1.  Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)

Authors:  E Mamounas; S Wieand; N Wolmark; H D Bear; J N Atkins; K Song; J Jones; H Rockette
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

Review 2.  Scatter factors and invasive growth.

Authors:  P M Comoglio; C Boccaccio
Journal:  Semin Cancer Biol       Date:  2001-04       Impact factor: 15.707

3.  Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis.

Authors:  S Dubé; F Heyen; M Jenicek
Journal:  Dis Colon Rectum       Date:  1997-01       Impact factor: 4.585

4.  Caspase-10 sensitizes breast carcinoma cells to TRAIL-induced but not tumor necrosis factor-induced apoptosis in a caspase-3-dependent manner.

Authors:  Ingo H Engels; Gudrun Totzke; Ute Fischer; Klaus Schulze-Osthoff; Reiner U Jänicke
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

5.  Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.

Authors:  Bengt Glimelius; Olav Dahl; Björn Cedermark; Anders Jakobsen; Søren M Bentzen; Hans Starkhammar; Henrik Grönberg; Ragnar Hultborn; Maria Albertsson; Lars Påhlman; Kjell-Magne Tveit
Journal:  Acta Oncol       Date:  2005       Impact factor: 4.089

6.  Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells.

Authors:  Ji Li; Peili Chen; Natasha Sinogeeva; Myriam Gorospe; Robert P Wersto; Francis J Chrest; Janice Barnes; Yusen Liu
Journal:  J Biol Chem       Date:  2002-10-17       Impact factor: 5.157

Review 7.  Adjuvant therapy for stage II colon cancer: an elephant in the living room?

Authors:  A Zaniboni; R Labianca
Journal:  Ann Oncol       Date:  2004-09       Impact factor: 32.976

8.  Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; C M Tangen; J S Ungerleider; W A Emerson; D C Tormey; J H Glick; M H Veeder; J A Mailliard
Journal:  Ann Intern Med       Date:  1995-03-01       Impact factor: 25.391

9.  Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma.

Authors:  Carmen Pingoud-Meier; Doris Lang; Anna J Janss; Lucy B Rorke; Peter C Phillips; Tarek Shalaby; Michael A Grotzer
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

10.  Determination of PCR efficiency in chelex-100 purified clinical samples and comparison of real-time quantitative PCR and conventional PCR for detection of Chlamydia pneumoniae.

Authors:  Tina Mygind; Svend Birkelund; Niels H Birkebaek; Lars Østergaard; Jørgen Skov Jensen; Gunna Christiansen
Journal:  BMC Microbiol       Date:  2002-07-09       Impact factor: 3.605

View more
  5 in total

1.  Relationship Between CASP9 and CASP10 Gene Polymorphisms and Cancer Susceptibility: Evidence from an Updated Meta-analysis.

Authors:  Saman Sargazi; Armin Zahedi Abghari; Hosna Sarani; Roghayeh Sheervalilou; Shekoufeh Mirinejad; Ramin Saravani; Ebrahim Eskandari
Journal:  Appl Biochem Biotechnol       Date:  2021-08-31       Impact factor: 2.926

2.  Proliferation index: a continuous model to predict prognosis in patients with tumours of the Ewing's sarcoma family.

Authors:  Samantha Brownhill; Dena Cohen; Sue Burchill
Journal:  PLoS One       Date:  2014-08-26       Impact factor: 3.240

3.  Silencer of death domains controls cell death through tumour necrosis factor-receptor 1 and caspase-10 in acute lymphoblastic leukemia.

Authors:  Adam Cisterne; Rana Baraz; Naveed I Khan; Robert Welschinger; Jordan Basnett; Carina Fung; Helen Rizos; Kenneth F Bradstock; Linda J Bendall
Journal:  PLoS One       Date:  2014-07-25       Impact factor: 3.240

4.  Caspase-10 inhibits ATP-citrate lyase-mediated metabolic and epigenetic reprogramming to suppress tumorigenesis.

Authors:  Rajni Kumari; Ruhi S Deshmukh; Sanjeev Das
Journal:  Nat Commun       Date:  2019-09-18       Impact factor: 14.919

5.  Identification of key genes and specific pathways potentially involved in androgen-independent, mitoxantrone-resistant prostate cancer.

Authors:  Sha Zhu; Lili Jiang; Liuyan Wang; Lingli Wang; Cong Zhang; Yu Ma; Tao Huang
Journal:  Cancer Manag Res       Date:  2019-01-03       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.